Fujitsu与Paradigum Health合作,到2030年吸引全球临床试验到日本。 Fujitsu partners with Paradigm Health to attract global clinical trials to Japan by 2030.

Fujitsu计划吸引全球临床试验到日本, 与制药公司及医疗机构合作, 透过新的医疗数据生态系统, Fujitsu plans to attract global clinical trials to Japan, combatting the 'drug loss' issue through a new medical data ecosystem in partnership with pharmaceutical companies and medical institutions. 它们的目标是利用人工智能改善其健康生活平台,并加快临床试验的数字化,与典型健康组织结成战略伙伴关系。 They aim to improve their Healthy Living Platform using AI and accelerate digitalization of clinical trials with a strategic partnership with Paradigm Health. 到2030年,它们的目标是收入200亿日元,有助于更快地获得药品和提供个性化治疗选择。 By 2030, they target 20.0 billion yen in revenue and contribute to faster medicine access and personalized treatment options.